Clinical Trial Update: Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation [Phase 2]

View source ↗

Summary

Clinical trial update on dabrafenib and trametinib in non-small cell lung cancer harboring the BRAF V600E mutation (Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MEKINIST (trametinib)
• TAFINLAR (DABRAFENIB)

Snippet

Sponsor: Asan Medical Center | Conditions: Cancer, Lung Cancer Metastatic | Phase 2 | Status: UNKNOWN